In fact, besides the importance of amplification or the mainly point mutations of the BCR-ABL gene, one of the most investigated resistant mechanisms in CML is that conferred by the efflux pump, Pgp. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.